Oral GLP-1 Medications Are Here — What You Need to Know Before Asking Your Doctor
By Dr. Chhaya Makhija, MD | Triple Board-Certified Endocrinologist & Lifestyle Medicine Specialist
What if you could get the benefits of a GLP-1 medication — without the needle, without the weekly injection, without the sting — simply by taking a pill?
That is no longer a hypothetical. It is here. And as someone who has been prescribing GLP-1 receptor agonists since they first received FDA approval, I want to make sure you have the right information before you walk into your next appointment.
In this post, I am breaking down two oral GLP-1 medications that have recently entered the space — what they are, how they work, who they are for, and most importantly, why the guidance of an endocrinologist matters more than ever when considering them. (GLP-1 medications are only the FDA-approved versions that are being discussed in this article)
What Is a GLP-1 Medication — and Why Does the Form It Comes In Matter?
GLP-1 receptor agonists are a class of medications that work by mimicking a natural gut hormone called glucagon-like peptide-1. They help regulate blood sugar, reduce appetite, slow gastric emptying, and — when used correctly with the right lifestyle foundation — can be genuinely transformative for people living with type 2 diabetes, obesity, and related metabolic conditions.
For years, these medications have only been available as injectable formulations — weekly subcutaneous injections that, for many patients, create a real barrier. Needle phobia is real. Injection site reactions are real. The commitment of a weekly shot can feel like one more thing to manage in an already demanding health journey.
The arrival of effective oral GLP-1 options changes that conversation significantly.
The Two Oral GLP-1 Medications You Should Know About
1. Wegovy Pill (Oral Semaglutide) FDA Approved: December 2025
Most people are familiar with Wegovy as an injectable. What is newer is its approval in pill form at significantly higher doses — and with expanded FDA-approved indications.
What it is approved for:
Obesity (BMI ≥ 30)
Overweight (BMI ≥ 27) with at least one weight-related comorbidity
Reduction of major adverse cardiovascular events — meaning heart attack, stroke, and cardiovascular death
Pediatric obesity in patients 12 years and older
MASH (metabolic-associated steatohepatitis, previously known as fatty liver disease)
How it works in pill form:
The molecule is identical to injectable semaglutide — it is a peptide. The challenge with peptides taken orally is that they are rapidly broken down by stomach acid and gut bacteria before they can be absorbed. To address this, the Wegovy pill is co-formulated with a compound called SNAC, which temporarily alters the local stomach pH and enhances absorption through the gastric lining. Because of this limited oral bioavailability — approximately 1 to 2% — the doses in pill form are dramatically higher than the injectable.
How to take it correctly — this matters:
Take on an empty stomach
Use no more than 4 to 6 ounces of plain water
Do not crush, chew, or cut the tablet — swallow whole
Wait at least 30 minutes before eating, drinking anything other than plain water, or taking other medications
These instructions are not optional. Food, coffee, or other beverages interfere with absorption and significantly reduce the medication's effectiveness.
Dose escalation: Starting at 1.5 mg daily, titrating gradually — 1.5 → 3 → 7 → 14 → 25 mg — based on tolerability and clinical guidance.
What the clinical trials showed: Published in the New England Journal of Medicine (2025), trials demonstrated approximately 13.6% to 15% body weight reduction over 68 to 71 weeks compared to placebo. For a person weighing 200 pounds, 15% represents approximately 30 pounds lost.
2. Foundayo (Orforglipron) FDA Approved: April 1, 2026
Foundayo is a different category of oral GLP-1 entirely — and it represents a genuinely exciting development in this space.
FDA-approved indication:
Chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one obesity-related comorbidity
What makes Fundio fundamentally different:
Unlike semaglutide — which is a peptide — Foundayo is a non-peptide, small-molecule, synthetic oral GLP-1 receptor agonist. Because it is not a peptide, it is not broken down by stomach acid or gut enzymes. It does not need a special absorption enhancer. It does not require fasting or water restrictions. It can be taken at any time of day, with or without food.
Its oral bioavailability is significantly higher — estimated at 40 to 70%, compared to 1 to 2% for oral semaglutide.
An important clinical nuance: Foundayo is a partial agonist of the GLP-1 receptor, meaning it binds to the same receptor but does not activate it with the same full force as injectable semaglutide. Clinical trials have shown approximately 11% body weight reduction — somewhat lower than injectable semaglutide or high-dose oral Wegovy. However, for patients where adherence and tolerability are the barriers, a medication that is genuinely easy to take may be far more clinically meaningful than a higher number on paper that a patient cannot sustain.
Dose escalation: Starting at 0.8 mg, titrating through 2.5 mg and 5.5 mg based on tolerability.
No dietary restrictions for administration — this alone sets it apart and may be a significant advantage for many patients.
Side Effects — What to Expect and How to Manage Them
Both oral GLP-1 medications share the gastrointestinal side effect profile common to the entire GLP-1 class: nausea, vomiting, diarrhea, and constipation are the most frequently reported. This is not a reason to avoid them. It is a reason to start them correctly.
What significantly reduces GI side effects:
Starting at the lowest possible dose and titrating slowly — never rushing
Ensuring adequate fiber intake before and during initiation
Maintaining consistent hydration and regular bowel habits
Avoiding high-fat meals, late-night eating, and large portions
Increasing protein intake to preserve muscle mass during weight loss
Understanding that nausea is almost always dose-dependent and temporary — it improves with time and proper titration
I have seen this story many times in my practice. Patients who tried a GLP-1 elsewhere and stopped because of side effects — who, with the right preparation, the right starting dose, and the right lifestyle foundation, go on to tolerate the medication beautifully and achieve transformative outcomes. The side effects were never the medication failing them. It was the absence of a complete plan.
Why You Need an Endocrinologist for GLP-1 Medications — Not Just a Prescription
GLP-1 receptor agonists are among the most powerful metabolic tools we have in medicine today. But a prescription is not a plan.
As endocrinologists, we were among the very first specialists to prescribe GLP-1 medications when they received FDA approval. This is our domain — the hormonal, metabolic, and endocrine systems that these medications interact with. The expertise required to use them well goes far beyond writing a script.
What working with a specialist endocrinologist provides:
Correct patient selection and indication assessment. Not every GLP-1 medication is appropriate for every patient. Contraindications must be reviewed — including personal or family history of thyroid cancer, pancreatitis, and other conditions. The right medication depends on your specific medical history, your other medications, your metabolic goals, and your lifestyle.
Personalized dose titration. The single most common reason patients discontinue GLP-1 medications is side effects that occur because they were escalated too quickly. An endocrinologist guides titration based on your individual tolerability — not a generic schedule.
Drug interaction review. GLP-1 medications affect gastric motility, which can alter the absorption of other medications you are taking. A thorough review of your full medication and supplement list is essential before initiation.
Lifestyle preparation and optimization. The clinical trials for these medications studied them in combination with reduced-calorie diet and increased physical activity. That is not a footnote — that is the design of how they work. Fiber intake, protein targets, meal timing, hydration, exercise guidance — these are the foundation that determines whether the medication delivers its full potential.
Ongoing monitoring. Blood glucose, kidney function, thyroid markers, weight trajectory, and body composition — all require monitoring at appropriate intervals. The goal is not just the number on the scale. It is preserving muscle mass, improving metabolic markers, and protecting long-term health.
Knowing when oral versus injectable is the right choice. There are clinical scenarios where transitioning from injectable GLP-1 to an oral formulation makes excellent sense — for example, a patient who has achieved their health goals and is now looking to maintain with a lower-burden regimen. There are also scenarios where the oral formulation is not the right choice. This decision requires a specialist.
Navigating Insurance Coverage — and Cost-Effective Alternatives
One of the most common questions I receive about GLP-1 medications — and one of the most important — is whether insurance will cover them.
The honest answer: it depends, and it requires active advocacy.
Insurance coverage for GLP-1 medications varies significantly by plan, employer, and state. Coverage for obesity indications has historically been more restricted than for type 2 diabetes indications — though this is evolving.
As your endocrinologist, part of my role is to navigate this on your behalf. This includes submitting prior authorization requests with appropriate clinical documentation, writing letters of medical necessity, appealing denials when clinically warranted, and identifying manufacturer patient assistance programs.
If coverage is denied or cost is a barrier — there are options. There are FDA-approved, cost-effective pathways within the GLP-1 class, and a good endocrinologist will help you identify them rather than leaving you to figure it out alone. The conversation about cost should never prevent a patient from accessing the care they need. I have that conversation with every patient, and I work with them to find a real path forward.
5 Questions to Ask Your Endocrinologist About Oral GLP-1 Medications
Before starting any GLP-1 medication — oral or injectable — here is what you should be asking:
Am I a candidate for an oral GLP-1 based on my medical history, current medications, and health goals?
Which oral GLP-1 is more appropriate for my situation — and how does it compare to the injectable option?
What lifestyle preparation should I complete before starting — and what do I need to do during titration to minimize side effects?
Will my insurance cover this, and if not, what are the realistic, cost-effective options available to me?
How will we track whether this is working — and what does success look like beyond the scale?
If your clinician cannot answer these questions with depth and specificity, that is a signal worth paying attention to.
A Note on What "Health Goals" Actually Means
Health goals are not just the number on the scale.
The purpose of GLP-1 therapy — when done correctly — is to improve body composition, preserve and build muscle mass, reduce visceral fat, improve insulin sensitivity, lower cardiovascular risk, and support a lifestyle that is sustainable long after the medication becomes part of your routine.
Weight in pounds or kilograms is one data point. It is not the whole picture.
When I work with patients on GLP-1 therapy, I am tracking muscle mass, fat mass, metabolic markers, blood glucose trends, energy, sleep, and quality of life. That comprehensive view is what guides every decision — when to escalate the dose, when to hold, when to consider transitioning from injectable to oral, and what lifestyle interventions will maximize and sustain the results.
This is unified care. Science and lifestyle working together — simplified, personalized, and built around the person in front of me.
Ready to Have This Conversation?
If you are a California resident — or traveling to California — and you are ready to explore whether an oral GLP-1 medication is right for you, I would be honored to be your endocrinologist for this journey.
At Unified Endocrine & Diabetes Care, every consultation starts with your full story. Not just your most recent lab value. Not just your BMI. Your history, your lifestyle, your goals, your barriers — and a personalized plan that brings science and life together in a way that is actually sustainable.
Schedule your consultation at unifiedendocrinecare.com
Whether you are newly considering GLP-1 therapy, have tried it before without success, or are currently on an injectable and curious about transitioning to an oral option — let's have the right conversation.
This post is for educational purposes and does not constitute personal medical advice. Please consult with a qualified physician before initiating, changing, or discontinuing any medication.
Dr. Chhaya Makhija is a triple board-certified endocrinologist and lifestyle medicine specialist and founder of Unified Endocrine & Diabetes Care. Host of the podcast Hormones and Hope. Follow on Instagram and YouTube at @CHHAYAMAKHIJAMD
By Dr. Chhaya Makhija, MD, DipABLM
Board-Certified Endocrinologist | Lifestyle Medicine Physician | Founder, Unified Endocrine & Diabetes Care
Lafayette • Fresno • California Telemedicine (including Silicon Valley, Palo Alto, Menlo Park, San Francisco, Walnut Creek, Oakland, Sacramento)
Watch or Listen to the Full Episode
For a deeper dive into the science and real-world clinical nuance:
FAQs about GLP-1s
-
They can be highly effective for the right person, but they are not magic. Sustainable results come from combining medication with nutrition, strength training, and long term habits.
-
Those terms usually reflect rapid fat loss and loss of lean muscle. Strength training, adequate protein, and slower titration can help protect body composition.
-
Constipation and nausea are common early on. Most side effects are gut related and can often be managed with slow dose increases and a clear plan.
-
Many people regain weight if they stop abruptly without a strategy. Some can taper successfully with strong lifestyle structure and careful monitoring, but rebound is common.
-
This episode focuses on FDA approved medications studied in clinical trials. If you are considering any version, discuss safety, sourcing, and evidence with your clinician.
Medical note: This blog is for education and does not replace personalized medical advice. Medication decisions should be made with your prescribing clinician based on your health history and goals.